Subscribe

Endometrial Cancer

LEAP-001: Lenvatinib plus Pembrolizumab vs. Chemotherapy as First-Line Therapy for Advanced Endometrial Cancer

First-line lenvatinib plus pembrolizumab did not significantly improve PFS or OS compared to chemotherapy in mismatch repair-proficient (pMMR) advanced endometrial cancer. Toxicity was higher in the experimental arm but manageable. dMMR exploratory analysis shows promise in this subgroup.

Keynote B21 - Pembrolizumab in High-Risk Endometrial Cancer (Video Explainer)

Video Explaining B-21 Trial

KEYNOTE-B21: Pembrolizumab Plus Adjuvant Chemotherapy in High-Risk Endometrial Cancer

Adjuvant Pembrolizumab did not improve DFS in high-risk endometrial cancer population

Westin LNG-IUD Phase II (2021): Levonorgestrel IUD for Complex Atypical Hyperplasia and Early Endometrial Cancer

ATtend Trial: Atezolizumab + chemotherapy for advanced or recurrent endometrial cancer

Atezolizumab with chemotherapy improved progression-free survival in advanced or recurrent endometrial carcinoma, especially in dMMR tumors, though overall survival hasn't shown significant benefit yet. In the pMMR population, no significant PFS or OS benefit was observed; OS benefit is minimal.

SIENDO: Oral Selinexor Maintenance After First-Line Chemotherapy in Advanced or Recurrent Endometrial Cancer

GOG 238: Radiation With or Without Cisplatin in Endometrial Cancer

Adding cisplatin to radiation therapy does not improve PFS or OS for patients with localized recurrences of endometrial cancer and results in higher toxicity rates. Radiation therapy alone remains an effective treatment for these patients.

ENGOT-EN5/GOG-3055/SIENDO: Selinexor in Endometrial Cancer (Phase II)

Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for

GOG 3007: Megace Tamoxifen vs Letrozole Everolimus

Both treatment arms demonstrated clinically meaningful efficacy in patients with recurrent endometrial carcinoma. The combination of everolimus and letrozole showed a non-significant trend toward improved survival outcomes compared to standard hormonal therapy.

TOTEM Trial: Intensive vs. Minimalist Follow-up in Endometrial Cancer

An intensive follow-up in patients treated for endometrial cancer does not improve overall survival or relapse detection significantly compared to a minimalist approach.